Pramlintide acetate is an anti-diabetic agent used as an adjunctive treatment for both type 1 and type 2 diabetes mellitus, particularly in patients who fail to achieve desired glycemic control with insulin alone or in combination with sulfonylureas or metformin; it is also under investigation for the treatment of colorectal cancer, showing dose-dependent inhibition of HCT-116 and HT-29 cell growth in vitro and synergistic antiproliferative effects when combined with 5-fluorouracil, oxaliplatin, or irinotecan.